Review of the renal endpoints used in cardiovascular safety clinical trials in type 2 diabetes mellitus patients and their importance in primary care.

Autor: Górriz JL; Nephrology Department, Hospital Clínico Universitario, INCLIVA, Valencia, Spain; Universidad de Valencia, Valencia, Spain; Grupo Español de Estudio de Nefropatía Diabética (GEENDIAB), Spain. Electronic address: jlgorriz@uv.es., Cos Claramunt FX; Innovation and Health in Primary Care Barcelona City, Gerencia Barcelona Ciutat, Institut Català de la Salut, Barcelona, Spain; Universidad Autónoma de Barcelona, Foundation University Institute for Primary Health Care Research Jordi Gol i Gurina (IDIAPJGol), Barcelona, Spain; Primary Care Diabetes Europe (PCDE), Antwerpen, Belgium., Duque N; Eli Lilly and Company, Madrid, Spain., Matali A; Boehringer Ingelheim, Spain.
Jazyk: angličtina
Zdroj: Primary care diabetes [Prim Care Diabetes] 2019 Dec; Vol. 13 (6), pp. 485-494. Date of Electronic Publication: 2019 Aug 07.
DOI: 10.1016/j.pcd.2019.07.001
Abstrakt: Chronic kidney disease (CKD) is one of the most common complications of type 2 diabetes mellitus (T2DM). Furthermore, CKD confers a considerable increase in the risk of cardiovascular (CV) morbidity and mortality. In line with the need to improve knowledge in this field, this article aims to describe the renal endpoints used in the different cardiovascular outcome trials (CVOTs). The objective is to better know the renal variables used in the different CVOTs in order to optimize the implementation of advances in the prevention of progressive diabetic kidney disease in patients with T2DM in clinical practice.
(Copyright © 2019 Primary Care Diabetes Europe. Published by Elsevier Ltd. All rights reserved.)
Databáze: MEDLINE
Externí odkaz: